The University of Pennsylvania’s Center for Cellular Immunotherapies, led by cell therapy pioneer Dr. Carl June, has entered into a cancer treatment collaboration with Candel Therapeutics.
This new approach to CAR-T therapy will involve mRNA therapy that directs cells in the body to make proteins to prevent or fight disease.
Penn Spinout Interius BioTherapeutics Is Developing Tools to Perform Cell and Gene Engineering Directly in the Human Body
The hope is that this new technology could simplify the process of CAR-T cell therapy and make gene therapy widely available as a one-time injection to a much larger number of patients.
In this Science Friday interview, Dr. Carl June discusses CAR-T's continued use in battling new blood cancers, as well as its future potential for treating solid state cancers and autoimmune diseases.
Penn spinout Verismo Therapeutics Makes Agreement to Fund University Research of KIR-CAR platform of Car-T to Target Solid Tumors
Learn about Penn spinout Verismo Therapeutics' agreement to fund four years of university research of KIR-CAR platform of Car-T to target solid tumors.
Learn about Dr. Bruce Levine's predictions for the future uses of Car-T therapy.
This collaboration will take place through company-sponsored pre-clinical research studies in the laboratory of Avery Posey, PhD, an assistant professor at the Perelman School of Medicine.
Five years after Penn and Novartis made history with the FDA approval of Kymriah, a recent study shows the long-term impact of the medication on patient remission rates.